|Category:||Emerging Biotech Company|
|Date:||April 24, 2023|
Asterivir, a spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL), is developing a broad-spectrum antiviral platform with a unique mechanism of action. Asterivir’s medicines have shown efficacy in-vitro against a wide variety of viruses and in-vivo against influenza, RSV, HSV-2 and SARS-CoV-2. Much as penicillin revolutionised the treatment of bacterial infections 100+ years ago, Asterivir has the ambition to do the same for viral infections today.